TY - JOUR
T1 - Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
AU - OPTIC Consortium
AU - ISARIC4C consortium
AU - Tuekprakhon, Aekkachai
AU - Nutalai, Rungtiwa
AU - Dijokaite-Guraliuc, Aiste
AU - Zhou, Daming
AU - Ginn, Helen M.
AU - Selvaraj, Muneeswaran
AU - Liu, Chang
AU - Mentzer, Alexander J.
AU - Supasa, Piyada
AU - Duyvesteyn, Helen M.E.
AU - Das, Raksha
AU - Skelly, Donal
AU - Ritter, Thomas G.
AU - Amini, Ali
AU - Bibi, Sagida
AU - Adele, Sandra
AU - Johnson, Sile Ann
AU - Constantinides, Bede
AU - Webster, Hermione
AU - Temperton, Nigel
AU - Klenerman, Paul
AU - Barnes, Eleanor
AU - Dunachie, Susanna J.
AU - Crook, Derrick
AU - Pollard, Andrew J.
AU - Lambe, Teresa
AU - Goulder, Philip
AU - Paterson, Neil G.
AU - Williams, Mark A.
AU - Hall, David R.
AU - Conlon, Christopher
AU - Deeks, Alexandra
AU - Frater, John
AU - Frending, Lisa
AU - Gardiner, Siobhan
AU - Jämsén, Anni
AU - Jeffery, Katie
AU - Malone, Tom
AU - Phillips, Eloise
AU - Rothwell, Lucy
AU - Stafford, Lizzie
AU - Fry, Elizabeth E.
AU - Huo, Jiandong
AU - Mongkolsapaya, Juthathip
AU - Ren, Jingshan
AU - Stuart, David I.
AU - Screaton, Gavin R.
N1 - Publisher Copyright:
© 2022 The Author(s)
PY - 2022/7/7
Y1 - 2022/7/7
N2 - The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread rapidly to become globally dominant and has split into a number of sublineages. BA.1 dominated the initial wave but has been replaced by BA.2 in many countries. Recent sequencing from South Africa's Gauteng region uncovered two new sublineages, BA.4 and BA.5, which are taking over locally, driving a new wave. BA.4 and BA.5 contain identical spike sequences, and although closely related to BA.2, they contain further mutations in the receptor-binding domain of their spikes. Here, we study the neutralization of BA.4/5 using a range of vaccine and naturally immune serum and panels of monoclonal antibodies. BA.4/5 shows reduced neutralization by the serum from individuals vaccinated with triple doses of AstraZeneca or Pfizer vaccine compared with BA.1 and BA.2. Furthermore, using the serum from BA.1 vaccine breakthrough infections, there are, likewise, significant reductions in the neutralization of BA.4/5, raising the possibility of repeat Omicron infections.
AB - The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread rapidly to become globally dominant and has split into a number of sublineages. BA.1 dominated the initial wave but has been replaced by BA.2 in many countries. Recent sequencing from South Africa's Gauteng region uncovered two new sublineages, BA.4 and BA.5, which are taking over locally, driving a new wave. BA.4 and BA.5 contain identical spike sequences, and although closely related to BA.2, they contain further mutations in the receptor-binding domain of their spikes. Here, we study the neutralization of BA.4/5 using a range of vaccine and naturally immune serum and panels of monoclonal antibodies. BA.4/5 shows reduced neutralization by the serum from individuals vaccinated with triple doses of AstraZeneca or Pfizer vaccine compared with BA.1 and BA.2. Furthermore, using the serum from BA.1 vaccine breakthrough infections, there are, likewise, significant reductions in the neutralization of BA.4/5, raising the possibility of repeat Omicron infections.
KW - antibody escape
KW - BA.4
KW - BA.5
KW - COVID-19
KW - Omicron
KW - SARS-CoV-2
KW - variant
KW - VoC
UR - https://www.scopus.com/pages/publications/85133200963
U2 - 10.1016/j.cell.2022.06.005
DO - 10.1016/j.cell.2022.06.005
M3 - Article
C2 - 35772405
AN - SCOPUS:85133200963
SN - 0092-8674
VL - 185
SP - 2422-2433.e13
JO - Cell
JF - Cell
IS - 14
ER -
SDG 3 Good Health and Well-being